Lee Rebecca A, Chang Maggie, Tsay Ariel, Lee Yeong Rim, Li Danielle, Yiv Nicholas, Tian Sharon, Zhao Michelle, O'Brien Richard M, Wang Jen-Chywan
Endocrinology Graduate Program, University of California Berkeley, Berkeley, CA.
Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, CA.
Diabetes. 2023 Nov 1;72(11):1534-1546. doi: 10.2337/db22-0605.
It is well established that chronic glucocorticoid exposure causes hyperglycemia. While glucocorticoid receptor (GR) stimulates hepatic gluconeogenic gene transcription, additional mechanisms are activated by chronic glucocorticoid exposure to enhance gluconeogenesis. We found that chronic glucocorticoid treatment activated sphingosine-1-phosphate (S1P)-mediated signaling. Hepatic knockdown of hepatic S1P receptor 1 (S1PR1) had no effect on chronic glucocorticoid-induced glucose intolerance but elevated fasting plasma insulin levels. In contrast, hepatic S1PR3 knockdown exacerbated chronic glucocorticoid-induced glucose intolerance without affecting fasting plasma insulin levels. Finally, hepatic S1PR2 knockdown attenuated chronic glucocorticoid-induced glucose intolerance and reduced fasting plasma insulin levels. Here, we focused on dissecting the role of S1PR2 signaling in chronic glucocorticoid response on glucose homeostasis. We found that chronic glucocorticoid-induced hepatic gluconeogenesis, gluconeogenic gene expression, and GR recruitment to the glucocorticoid response elements (GREs) of gluconeogenic genes were all reduced in hepatic S1PR2 knockdown male mice. Hepatic S1PR2 knockdown also enhanced glucocorticoid suppression of RAR-related orphan receptor γ (RORγ) expression. Hepatic RORγ overexpression in hepatic S1PR2 knockdown mice restored glucocorticoid-induced glucose intolerance, gluconeogenic gene expression, and GR recruitment to their GREs. Conversely, RORγ antagonist and the reduction of hepatic RORγ expression attenuated such glucocorticoid effects. Thus, chronic glucocorticoid exposure induces an S1PR2-RORγ axis to cooperate with GR to enhance hepatic gluconeogenesis. Overall, this work provides novel mechanisms of and pharmaceutical targets against steroid-induced hyperglycemia.
长期暴露于糖皮质激素会导致高血糖,这一点已得到充分证实。虽然糖皮质激素受体(GR)可刺激肝脏糖异生基因转录,但长期暴露于糖皮质激素会激活其他机制以增强糖异生作用。我们发现,长期使用糖皮质激素治疗会激活鞘氨醇-1-磷酸(S1P)介导的信号传导。肝脏中鞘氨醇-1-磷酸受体1(S1PR1)的敲低对长期糖皮质激素诱导的葡萄糖不耐受没有影响,但会提高空腹血浆胰岛素水平。相反,肝脏中S1PR3的敲低会加剧长期糖皮质激素诱导的葡萄糖不耐受,而不影响空腹血浆胰岛素水平。最后,肝脏中S1PR2的敲低可减轻长期糖皮质激素诱导的葡萄糖不耐受,并降低空腹血浆胰岛素水平。在此,我们专注于剖析S1PR2信号在长期糖皮质激素对葡萄糖稳态反应中的作用。我们发现,在肝脏S1PR2敲低的雄性小鼠中,长期糖皮质激素诱导的肝脏糖异生、糖异生基因表达以及GR募集到糖异生基因的糖皮质激素反应元件(GREs)均降低。肝脏S1PR2敲低还增强了糖皮质激素对视黄酸相关孤儿受体γ(RORγ)表达的抑制作用。在肝脏S1PR2敲低的小鼠中,肝脏RORγ的过表达恢复了糖皮质激素诱导的葡萄糖不耐受、糖异生基因表达以及GR募集到其GREs。相反,RORγ拮抗剂和肝脏RORγ表达的降低减弱了这种糖皮质激素作用。因此,长期暴露于糖皮质激素会诱导一个S1PR2-RORγ轴与GR协同作用以增强肝脏糖异生。总体而言,这项工作提供了针对类固醇诱导的高血糖的新机制和药物靶点。